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background: Oxidized phospholipids (OxPL), present on OxLDL and Lp(a), are mediators of inflammation and cardiovascular disease 
(CVD) and are particularly enriched in vulnerable lesions. OxPL/apoB is an established biomarker that predicts anatomical CVD and 
events. Among lipoproteins, OxPL are primarily carried by Lp(a) and OxPL/apoB primarily reflects the biological activity of Lp(a). Previous 
studies have shown that statins, low fat diet and garlic increase OxPL/apoB, in concert with increases in Lp(a). However, changes in OxPL/
apoB with Lp(a)-lowering agents are not well studied.
Methods: OxPL/apoB levels were measured in 591 patients at baseline and 24 weeks post therapy with ezetimibe/simvastatin (E/S) 
(10/20mg) + Niacin (N) (to 2g), N or E/S monotherapy in a randomized, double-blind trial of hypercholesterolemic patients.
Results: Niacin lowered OxPL/apoB by 17% at 24 weeks (Figure). In contrast, E/S+Niacin and E/S increased OxPL/apoB by 50% and 
40.4%, respectively.
conclusion:  This study demonstrates a significant decrease in OxPL/apoB with Niacin. The effect of Niacin on OxPL/apoB, particularly in 
patients with elevated baseline levels, may provide insights explaining the AIM-HIGH and HPS2-THRIVE results.
